Picture supply: Getty Pictures
For many who have invested, Nvidia By persevering with to purchase and maintain the shares at the moment, the returns have been wonderful. It achieved an annualized return of 75.3% in pound phrases over 10 years.
one FTSE250 Funding trusts that benefited from Baillie Gifford US Progress Belief. From March 2018 to late 2025, funding in Nvidia elevated 3,155%!
Baillie Gifford and Nvidia teslait is value taking note of what new shares you are shopping for. And one new identify within the US Progress Belief portfolio caught my eye.
Let’s take a better have a look at this obscure firm (which not too long ago went public and is already one of many belief’s massive holdings) to see what all of the fuss is about.
inventory
1 billion twang (NASDAQ:BLLN) is a medical diagnostics firm. Its quantitative counting template platform is the one patented know-how able to counting DNA molecules with singular precision at massive scale.
As we seemed extra carefully on the firm, we discovered some attention-grabbing issues. First, BillionToOne operates in two high-growth diagnostic markets: non-invasive prenatal testing and most cancers testing. The corporate estimates its complete addressable market to be roughly $100 billion in the US alone.
It is encouraging to see the corporate profiting from this chance, with Q3 gross sales up 117% year-over-year to $83.5 million. We carried out 165,000 exams, a rise of 52%.
Administration expects 2026 gross sales to be between $415 million and $430 million, representing development of 40% to 45%. Many of the firm’s income comes from prenatal testing, which makes use of solely the mom’s blood to display for illnesses resembling cystic fibrosis and sickle cell, however most cancers testing can be doing very nicely.
One other optimistic is that the corporate is not burning via money. For the total 12 months, working revenue is anticipated to be within the black, and the gross revenue margin is anticipated to be excessive at roughly 70%. Due to this fact, this could be a very worthwhile enterprise.
Lastly, the corporate’s market cap in the present day is simply $3.9 billion. At the moment, that is really not that massive of a deal. If the corporate seizes future enterprise alternatives, it has the potential to develop even bigger.
In spite of everything, Nvidia’s market cap was roughly this measurement in 2013.
Our long-term aim is to construct a category-defining, generational firm and develop into a member of the S&P 500..
1 billion twang
my first level
Taking a step again, listed below are some issues we see that point out BillionToOne has the potential to develop into a prime development inventory. In contrast to many early-stage development firms, the corporate is already aiming for top margins and sustained profitability via 2026.
Added to that is strong institutional investor help and large-scale worldwide growth alternatives. The corporate can be engaged on exams to detect most cancers early, which might be its most enjoyable market.
Nevertheless, it is too early to name this an outright winner, a lot much less assume it has an opportunity like Nvidia. There’s plenty of competitors on this discipline guardant well being and Nateraand I fear that new diagnostic breakthroughs will threaten the corporate’s know-how sooner or later.
However, the price-to-sales a number of is almost 10x, so there’s already loads of development constructed into the present valuation.
All in all, I feel this can be a work value taking note of. BillionToOne will report fourth-quarter earnings in early March.